Yatiri Bio Accurately Predicts AML Drug Response in Blinded Study Using Foghorn’s FHD-286
· Financial Post
About Yatiri Bio
Yatiri Bio is a precision medicine company focused on the identification and validation of biomarkers that predict therapeutic responses in oncology. The company develops predictive assays to stratify patients prior to treatment, with the goal of improving clinical trial success rates and accelerating the development of effective therapies. Yatiri Bio is already advancing partnerships with biopharmaceutical companies seeking to de-risk clinical development by integrating biomarker-based patient selection into early-stage trials. The company plans to expand its ProteoCharts™ across hematologic and solid tumors in 2026, including MDS, ovarian cancer, prostate, breast, and CRC. Pharmaceutical companies interested in a collaboration in these or other indications should reach out to [email protected] for more information. Read More
Yatiri Bio is a precision medicine company focused on the identification and validation of biomarkers that predict therapeutic responses in oncology. The company develops predictive assays to stratify patients prior to treatment, with the goal of improving clinical trial success rates and accelerating the development of effective therapies. Yatiri Bio is already advancing partnerships with biopharmaceutical companies seeking to de-risk clinical development by integrating biomarker-based patient selection into early-stage trials. The company plans to expand its ProteoCharts™ across hematologic and solid tumors in 2026, including MDS, ovarian cancer, prostate, breast, and CRC. Pharmaceutical companies interested in a collaboration in these or other indications should reach out to [email protected] for more information. Read More
Visit truewildgame.online for more information.